Business Context and Reporting Period
This Form 8-K is a current report filed by AmerisourceBergen Corporation (now Cencora, Inc.) on February 1, 2023. The filing announces the results of operations for the fiscal quarter ended December 31, 2022. The report incorporates by reference a news release (Exhibit 99.1) containing the detailed earnings announcement.
Key Financial Metrics
The provided filing text serves as a notification of the earnings release and does not contain specific numerical data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document. Investors must refer to the attached news release (Exhibit 99.1) for these figures.
Material Changes
The filing text does not provide specific details regarding material changes in financial performance compared to the prior comparable period. It only confirms that results for the quarter ended December 31, 2022, have been issued.
Guidance, Outlook, and Management Commentary
Management scheduled a conference call and webcast for February 1, 2023, at 8:30 a.m. Eastern time to discuss the quarterly results and related matters. Slides and a link to the call were made available on the company's investor relations website. The filing explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific revenue and earnings per share figures in the attached news release (Exhibit 99.1).
- Review the conference call slides and transcript for management's commentary on the pharmaceutical supply chain and margin trends.
- Confirm the company's forward-looking guidance for the full fiscal year 2023.
- Check for any updates on the company's rebranding from AmerisourceBergen to Cencora.